Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases?—A propensity score analysis

Ouyang, Huaqiang LU ; Ma, Weidong ; Jiang, Xiangli ; Sandström Gerdtsson, Anna LU ; Liu, Donglin LU and Pan, Zhanyu (2023) In Expert Review of Gastroenterology and Hepatology
Abstract
Background
For advanced pancreatic cancer, pulmonary metastases (PM) have been considered favorable factors compared to metastases of other sites, but it remains unknown whether the prognosis of patients with synchronous liver and lung metastases is better than that of non-PM.

Methods
Data was derived from a two-decade cohort and included 932 cases of pancreatic adenocarcinoma with synchronous liver metastases (PACLM). Propensity score matching (PSM) was applied to balance 360 selected cases, grouped into PM (n = 90) and non-PM (n = 270). Overall survival (OS) and survival-related factors were analyzed.

Results
In PSM-adjusted data, the median OS was 7.3 and 5.8 months, for PM and non-PM, respectively (p =... (More)
Background
For advanced pancreatic cancer, pulmonary metastases (PM) have been considered favorable factors compared to metastases of other sites, but it remains unknown whether the prognosis of patients with synchronous liver and lung metastases is better than that of non-PM.

Methods
Data was derived from a two-decade cohort and included 932 cases of pancreatic adenocarcinoma with synchronous liver metastases (PACLM). Propensity score matching (PSM) was applied to balance 360 selected cases, grouped into PM (n = 90) and non-PM (n = 270). Overall survival (OS) and survival-related factors were analyzed.

Results
In PSM-adjusted data, the median OS was 7.3 and 5.8 months, for PM and non-PM, respectively (p = 0.16). Multivariate analysis revealed that male gender, poor performance status, higher hepatic tumor burden, ascites, elevated carbohydrate antigen 19–9, and lactate dehydrogenase were factors of poor survival (p < 0.05). Chemotherapy was the only independent significant factor of favorable prognosis (p < 0.05).

Conclusion
Although lung involvement was indicated to be a favorable prognostic factor for patients with PACLM in the whole cohort, PM were not associated with better survivals in the subset of cases subjected to PSM adjustment. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Expert Review of Gastroenterology and Hepatology
publisher
Expert Reviews Ltd.
external identifiers
  • pmid:36803208
  • scopus:85149295012
ISSN
1747-4124
DOI
10.1080/17474124.2023.2183497
language
English
LU publication?
yes
id
29e6358a-3fda-4b7e-a1b7-9f4682a542fa
date added to LUP
2023-02-24 09:39:15
date last changed
2023-03-30 04:11:46
@article{29e6358a-3fda-4b7e-a1b7-9f4682a542fa,
  abstract     = {{Background<br/>For advanced pancreatic cancer, pulmonary metastases (PM) have been considered favorable factors compared to metastases of other sites, but it remains unknown whether the prognosis of patients with synchronous liver and lung metastases is better than that of non-PM.<br/><br/>Methods<br/>Data was derived from a two-decade cohort and included 932 cases of pancreatic adenocarcinoma with synchronous liver metastases (PACLM). Propensity score matching (PSM) was applied to balance 360 selected cases, grouped into PM (n = 90) and non-PM (n = 270). Overall survival (OS) and survival-related factors were analyzed.<br/><br/>Results<br/>In PSM-adjusted data, the median OS was 7.3 and 5.8 months, for PM and non-PM, respectively (p = 0.16). Multivariate analysis revealed that male gender, poor performance status, higher hepatic tumor burden, ascites, elevated carbohydrate antigen 19–9, and lactate dehydrogenase were factors of poor survival (p &lt; 0.05). Chemotherapy was the only independent significant factor of favorable prognosis (p &lt; 0.05).<br/><br/>Conclusion<br/>Although lung involvement was indicated to be a favorable prognostic factor for patients with PACLM in the whole cohort, PM were not associated with better survivals in the subset of cases subjected to PSM adjustment.}},
  author       = {{Ouyang, Huaqiang and Ma, Weidong and Jiang, Xiangli and Sandström Gerdtsson, Anna and Liu, Donglin and Pan, Zhanyu}},
  issn         = {{1747-4124}},
  language     = {{eng}},
  month        = {{02}},
  publisher    = {{Expert Reviews Ltd.}},
  series       = {{Expert Review of Gastroenterology and Hepatology}},
  title        = {{Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases?—A propensity score analysis}},
  url          = {{http://dx.doi.org/10.1080/17474124.2023.2183497}},
  doi          = {{10.1080/17474124.2023.2183497}},
  year         = {{2023}},
}